DaVita Inc. (NYSE:DVA) Shares Purchased by Convergence Investment Partners LLC

Convergence Investment Partners LLC raised its position in DaVita Inc. (NYSE:DVA) by 33.2% during the 4th quarter, Holdings Channel reports. The firm owned 11,389 shares of the company’s stock after acquiring an additional 2,836 shares during the quarter. Convergence Investment Partners LLC’s holdings in DaVita were worth $1,703,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after purchasing an additional 92,014 shares during the last quarter. KBC Group NV boosted its stake in shares of DaVita by 0.8% during the fourth quarter. KBC Group NV now owns 316,155 shares of the company’s stock valued at $47,281,000 after acquiring an additional 2,636 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of DaVita by 23.9% during the third quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock valued at $47,874,000 after acquiring an additional 56,389 shares during the last quarter. Nordea Investment Management AB boosted its stake in shares of DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock valued at $39,712,000 after acquiring an additional 12,339 shares during the last quarter. Finally, abrdn plc boosted its stake in shares of DaVita by 1.2% during the third quarter. abrdn plc now owns 189,065 shares of the company’s stock valued at $30,719,000 after acquiring an additional 2,180 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Ratings Changes

Separately, Barclays increased their target price on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, DaVita presently has an average rating of “Hold” and a consensus price target of $162.80.

DaVita Stock Performance

NYSE DVA opened at $154.98 on Wednesday. The business’s 50-day moving average price is $161.41 and its 200 day moving average price is $157.91. DaVita Inc. has a twelve month low of $119.42 and a twelve month high of $179.60. The company has a market capitalization of $12.40 billion, a PE ratio of 14.43, a price-to-earnings-growth ratio of 0.79 and a beta of 0.94. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, research analysts predict that DaVita Inc. will post 10.93 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.